Sibeprenlimab is being investigated for the treatment of IgA nephropathy (IgAN); it inhibits pathogenic immunoglobulins (IgA and IgM) while preserving mRNA vaccine-induced antibody responses against SARS-CoV-2; it reduces urine protein-to-creatinine ratio (UPCR) and improves glomerular filtration rate (GFR).